Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346

1.

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases.

Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, Wu X, Kloc W, Izycka-Swieszewska E, Duchnowska R, Pęksa R, Biernat W, Jassem J, Nayyar N, Brastianos PK, Hall OM, Peer CJ, Figg WD, Pauly GT, Robinson C, Difilippantonio S, Bialecki E, Metellus P, Schneider JP, Steeg PS.

Nat Commun. 2018 Jul 13;9(1):2705. doi: 10.1038/s41467-018-05030-w.

PMID:
30006619
2.

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F.

Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30365-6. doi: 10.1016/S1470-2045(18)30365-6. [Epub ahead of print]

PMID:
29880291
3.

Systemic therapy for cervical carcinoma - current status.

Serkies K, Jassem J.

Chin J Cancer Res. 2018 Apr;30(2):209-221. doi: 10.21147/j.issn.1000-9604.2018.02.04.

4.

Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.

Duchnowska R, Loibl S, Jassem J.

Cancer Treat Rev. 2018 Jun;67:71-77. doi: 10.1016/j.ctrv.2018.05.004. Epub 2018 May 9. Review.

PMID:
29772459
5.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.

Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

PMID:
29753703
6.

Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.

Skrzypski M, Jassem J.

Cancer Treat Rev. 2018 May;66:114-121. doi: 10.1016/j.ctrv.2018.04.001. Epub 2018 Apr 5. Review.

PMID:
29738940
7.

"Teachable Moment" Interventions in Lung Cancer: Why Action Matters.

Dresler C, Warren GW, Arenberg D, Yang P, Steliga MA, Cummings KM, Stone E, Jassem J.

J Thorac Oncol. 2018 May;13(5):603-605. doi: 10.1016/j.jtho.2018.02.020. No abstract available.

PMID:
29703537
8.

MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.

Filipska M, Skrzypski M, Czetyrbok K, Stokowy T, Stasiłojć G, Supernat A, Jassem J, Żaczek AJ, Bigda J.

Lung Cancer. 2018 Apr;118:111-118. doi: 10.1016/j.lungcan.2018.02.002. Epub 2018 Feb 6.

PMID:
29571988
9.

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.

Müller V, Clemens M, Jassem J, Al-Sakaff N, Auclair P, Nüesch E, Holloway D, Shing M, Bang YJ.

BMC Cancer. 2018 Mar 15;18(1):295. doi: 10.1186/s12885-018-4183-2.

10.

Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation.

Hryciuk B, Szymanowski B, Romanowska A, Salt E, Wasąg B, Grala B, Jassem J, Duchnowska R.

Oncol Lett. 2018 Feb;15(2):1912-1916. doi: 10.3892/ol.2017.7473. Epub 2017 Nov 22.

11.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL.

Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.

PMID:
29433850
12.

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.

Duchnowska R, Sperinde J, Czartoryska-Arłukowicz B, Myśliwiec P, Winslow J, Radecka B, Petropoulos C, Demlova R, Orlikowska M, Kowalczyk A, Lang I, Ziółkowska B, Dębska-Szmich S, Merdalska M, Grela-Wojewoda A, Żawrocki A, Biernat W, Huang W, Jassem J.

Oncotarget. 2017 Oct 24;8(61):104149-104159. doi: 10.18632/oncotarget.22027. eCollection 2017 Nov 28.

13.

Dual HER2 Blockade.

Thomssen C, El Saghir NS, Francis PA, Jassem J, Rugo HS, Untch M.

Breast Care (Basel). 2017 Oct;12(5):345-349. doi: 10.1159/000484226. Epub 2017 Oct 30. No abstract available.

14.

Serum lipid profile discriminates patients with early lung cancer from healthy controls.

Ros-Mazurczyk M, Jelonek K, Marczyk M, Binczyk F, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Lung Cancer. 2017 Oct;112:69-74. doi: 10.1016/j.lungcan.2017.07.036. Epub 2017 Aug 1.

PMID:
29191603
15.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.

16.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

PMID:
29045519
17.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Oct;22(10):1281. doi: 10.1634/theoncologist.2016-0133erratum. No abstract available.

18.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.

J Clin Oncol. 2017 Oct 20;35(30):3449-3457. doi: 10.1200/JCO.2016.71.7629. Epub 2017 Aug 30.

PMID:
28854067
19.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

20.

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P.

ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. Review.

21.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.

PMID:
28838210
22.

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.

Roś-Mazurczyk M, Wojakowska A, Marczak Ł, Polański K, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Acta Biochim Pol. 2017;64(3):513-518. doi: 10.18388/abp.2017_1517. Epub 2017 Aug 12.

23.

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O.

J Clin Oncol. 2017 Oct 1;35(28):3189-3197. doi: 10.1200/JCO.2016.72.1068. Epub 2017 Jul 28.

PMID:
28753384
24.

Post-mastectomy radiation therapy after breast reconstruction: Indications, timing and results.

Jassem J.

Breast. 2017 Aug;34 Suppl 1:S95-S98. doi: 10.1016/j.breast.2017.06.037. Epub 2017 Jun 30. Review.

PMID:
28673536
25.

Long-Term Follow-Up of the Intergroup Exemestane Study.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC.

J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3.

26.

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation.

Senkus E, Szade J, Pieczyńska B, Kunc M, Pliszka A, Jassem J.

Histol Histopathol. 2018 Jan;33(1):55-64. doi: 10.14670/HH-11-887. Epub 2017 Mar 9.

PMID:
28276034
27.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Apr;22(4):375-e30. doi: 10.1634/theoncologist.2016-0133. Epub 2017 Mar 8. Erratum in: Oncologist. 2017 Oct;22(10 ):1281.

28.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

29.

Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer.

Serkies K, Jaśkiewicz J, Dziadziuszko R, Jassem J.

J Contemp Brachytherapy. 2016 Dec;8(6):492-496. doi: 10.5114/jcb.2016.64512. Epub 2016 Dec 9.

30.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva G, Novotny J, O'Reilly S, Salek T, Reiner M, Morrow PK, Choi MR, Whittaker S, Blanke C.

Clin Colorectal Cancer. 2017 Jun;16(2):103-114.e3. doi: 10.1016/j.clcc.2016.08.008. Epub 2016 Sep 7.

PMID:
28038865
31.

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH.

Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y.

PMID:
27975152
32.

PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients: Topic: Medical Oncology.

Herbst RS, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel DR.

J Thorac Oncol. 2016 Nov;11(11S):S304-S305. doi: 10.1016/j.jtho.2016.09.091. Epub 2016 Oct 28. No abstract available.

33.

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.

Szutowicz-Zielińska E, Konopa K, Kowalczyk A, Suszko-Każarnowicz M, Duchnowska R, Szczęsna A, Ratajska M, Sowa A, Limon J, Biernat W, Burzykowski T, Jassem J, Dziadziuszko R.

Oncotarget. 2017 Mar 7;8(10):17270-17278. doi: 10.18632/oncotarget.13793.

34.

Highlights from the San Antonio Breast Cancer Symposium 2015.

Jassem J.

ESMO Open. 2016 Feb 26;1(1):e000043. eCollection 2016.

35.

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.

Pavlidis N, Alba E, Berardi R, Bergh J, El Saghir N, Jassem J, Kosty M, Lopez RI, Lotz JP, Österlund P, Purkalne G, Dittrich C.

ESMO Open. 2016 Jan 18;1(1):e000004. eCollection 2016. No abstract available.

36.

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):110-120. doi: 10.1016/j.jtho.2016.09.002. Epub 2016 Sep 14.

37.

Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer.

Adamowicz K, Saad ED, Jassem J.

Cancer Treat Rev. 2016 Nov;50:194-199. doi: 10.1016/j.ctrv.2016.09.015. Epub 2016 Sep 30. Review.

PMID:
27718458
38.

Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer.

Duchnowska R, Jarząb M, Żebracka-Gala J, Matkowski R, Kowalczyk A, Radecka B, Kowalska M, Pfeifer A, Foszczyńska-Kłoda M, Musolino A, Czartoryska-Arłukowicz B, Litwiniuk M, Surus-Hyla A, Szabłowska-Siwik S, Karczmarek-Borowska B, Dębska-Szmich S, Głodek-Sutek B, Sosińska-Mielcarek K, Chmielowska E, Kalinka-Warzocha E, Olszewski WP, Patera J, Żawrocki A, Pliszka A, Tyszkiewicz T, Rusinek D, Oczko-Wojciechowska M, Jassem J, Biernat W; Polish Brain Metastasis Consortium.

Clin Breast Cancer. 2017 Apr;17(2):e65-e75. doi: 10.1016/j.clbc.2016.08.008. Epub 2016 Sep 8.

PMID:
27692773
39.

Systemic therapy for endometrial stromal sarcomas: current treatment options.

Serkies K, Pawłowska E, Jassem J.

Ginekol Pol. 2016;87(8):594-7. doi: 10.5603/GP.2016.0051. Review.

40.

Serum mass profile signature as a biomarker of early lung cancer.

Widlak P, Pietrowska M, Polanska J, Marczyk M, Ros-Mazurczyk M, Dziadziuszko R, Jassem J, Rzyman W.

Lung Cancer. 2016 Sep;99:46-52. doi: 10.1016/j.lungcan.2016.06.011. Epub 2016 Jun 16.

PMID:
27565913
41.

Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer.

Bobowicz M, Skrzypski M, Czapiewski P, Marczyk M, Maciejewska A, Jankowski M, Szulgo-Paczkowska A, Zegarski W, Pawłowski R, Polańska J, Biernat W, Jaśkiewicz J, Jassem J.

Clin Exp Metastasis. 2016 Dec;33(8):765-773. Epub 2016 Aug 2.

42.

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Šikić BI.

Oncologist. 2016 Oct;21(10):1183-1190. Epub 2016 Jul 8.

43.

Bright and dark sides of evidence-based medicine.

Jassem J.

Pol Arch Med Wewn. 2016 May 31;126(5):347-52. doi: 10.20452/pamw.3403. Epub 2016 May 5. Review.

44.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N.

Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.

PMID:
27132212
45.

Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.

Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, Czartoryska-Arłukowicz B, Olszewski WP, Och W, Kalinka-Warzocha E, Kozłowski W, Kowalczyk A, Loi S, Biernat W, Jassem J; Polish Brain Metastasis Consortium.

Breast Cancer Res. 2016 Apr 27;18(1):43. doi: 10.1186/s13058-016-0702-8.

46.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, Aisner DL, Doebele RC.

J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.

47.

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M; LUX-Breast 1 study group.

Lancet Oncol. 2016 Mar;17(3):357-66. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26.

PMID:
26822398
48.

Castleman's disease mimicking lymph node metastases in a young woman with laryngeal cancer.

Serkies K, Łazar-Poniatowska M, Seredyńska J, Biernat W, Jassem J.

Contemp Oncol (Pozn). 2016;20(5):421-424. doi: 10.5114/wo.2016.64608. Epub 2016 Dec 20.

49.

Alectinib in crizotinib-resistant, ALK-positive NSCLC.

Jassem J.

Lancet Oncol. 2016 Feb;17(2):134-135. doi: 10.1016/S1470-2045(15)00555-0. Epub 2015 Dec 19. No abstract available.

PMID:
26708154
50.

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.

Duchnowska R, Wysocki PJ, Korski K, Czartoryska-Arłukowicz B, Niwińska A, Orlikowska M, Radecka B, Studziński M, Demlova R, Ziółkowska B, Merdalska M, Hajac Ł, Myśliwiec P, Zuziak D, Dębska-Szmich S, Lang I, Foszczyńska-Kłoda M, Karczmarek-Borowska B, Żawrocki A, Kowalczyk A, Biernat W, Jassem J; Central and East European Oncology Group (CEEOG).

Oncotarget. 2016 Jan 5;7(1):550-64. doi: 10.18632/oncotarget.6375.

Supplemental Content

Loading ...
Support Center